{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T10:26:57Z","timestamp":1769596017450,"version":"3.49.0"},"reference-count":29,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2019,10,6]],"date-time":"2019-10-06T00:00:00Z","timestamp":1570320000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"funder":[{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2020,2]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Brentuximab vedotin (BV) is the first approved novel agent for salvage treatment of relapsed or refractory (R\/R) classical Hodgkin lymphoma (cHL) after autologous stem cell transplantation (ASCT). In this study, a literature\u2010based analysis was undertaken to assess, via an indirect treatment comparison, the comparative efficacy of BV to salvage chemotherapy as treatment for R\/R cHL patients following ASCT. This comparative effectiveness research was undertaken to support a reimbursement submission for BV to the Australian Pharmaceutical Benefits Advisory Committee. Retrospective analysis of individual patient data from four data sources demonstrated that the use of BV as first salvage treatment in cHL patients relapsing or progressing post\u2010ASCT achieved improvements in both clinical response and overall survival. More specifically, BV was associated with an incremental improvement of 22% in overall response rate compared to salvage chemotherapy. Five\u2010year overall survival and progression\u2010free survival rates were 92\u00b72% [95% confidence interval (CI): 85\u00b75\u201399\u00b73%] and 32\u00b72% (95% CI: 19\u00b71\u201354\u00b76%) respectively for BV, compared to 30\u00b75% (95% CI: 22\u00b72\u201342\u00b70%) and 3\u00b72% (95% CI: 1\u00b71\u20138\u00b79%) respectively for salvage chemotherapy. The encouraging results from this conservative analysis have the potential to support informed clinical management and funding decisions for the first salvage of cHL patients demonstrating recurrence after ASCT.<\/jats:p>","DOI":"10.1111\/bjh.16201","type":"journal-article","created":{"date-parts":[[2019,10,7]],"date-time":"2019-10-07T00:59:07Z","timestamp":1570409947000},"page":"540-549","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Brentuximab vedotin for the treatment of patients with relapsed or refractory Hodgkin lymphoma after autologous stem cell transplantation"],"prefix":"10.1111","volume":"188","author":[{"given":"Panayotis","family":"Kaloyannidis","sequence":"first","affiliation":[{"name":"King Fahad Specialist Hospital Dammam Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Hertzberg","sequence":"additional","affiliation":[{"name":"Prince of Wales Hospital, and University of NSW Randwick NSW Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kate","family":"Webb","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceuticals Sydney NSW Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Athanasios","family":"Zomas","sequence":"additional","affiliation":[{"name":"Takeda Europe &amp; Canada Business Unit (EUCAN) Zurich Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rudolf","family":"Schrover","sequence":"additional","affiliation":[{"name":"SYNEVi Pty Limited Chatswood NSW Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Hurst","sequence":"additional","affiliation":[{"name":"Health Economics and Outcomes Research Ltd Cardiff UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5183-1363","authenticated-orcid":false,"given":"Ian","family":"Jacob","sequence":"additional","affiliation":[{"name":"Health Economics and Outcomes Research Ltd Cardiff UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thalia","family":"Nikoglou","sequence":"additional","affiliation":[{"name":"Takeda Europe &amp; Canada Business Unit (EUCAN) Zurich Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1361-7531","authenticated-orcid":false,"given":"Joseph M.","family":"Connors","sequence":"additional","affiliation":[{"name":"BC Cancer Centre for Lymphoid Cancer and the University of British Columbia Vancouver BC Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2019,10,6]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.1.222"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2013.798868"},{"key":"e_1_2_9_4_1","unstructured":"Australian Government Department of Health(2016)Guidelines for preparing a submission to the Pharmaceutical Benefits Advisory. Committee Available https:\/\/pbac.pbs.gov.au\/content\/information\/files\/pbac-guidelines-version-5.pdf."},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-012-1530-2"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-02-699850"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.2403"},{"key":"e_1_2_9_8_1","volume-title":"R: A language and environment for statistical computing","author":"R Core Team","year":"2018"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428199609054778"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/ncponc1186"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-08-595801"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2011.07.020"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1704214"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2542"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.91.23.10962"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(93)92411-L"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2012.133"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.07727.x"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)60165-9"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-07-861641"},{"key":"e_1_2_9_21_1","volume-title":"Technology appraisal guidance [TA524]. Brentuximab vedotin for treating CD30\u2010positive Hodgkin lymphoma","author":"NICE","year":"2018"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2016.1219358"},{"key":"e_1_2_9_23_1","unstructured":"Pharmaceutical Benefits Scheme(2016)BRENTUXIMAB VEDOTIN Powder for I.V. infusion 50 mg Adcetris\u00ae Takeda Pharmaceuticals Australia Pty Ltd. Public Summary Document \u2013 November 2016 PBAC Meeting. Available http:\/\/www.pbs.gov.au\/industry\/listing\/elements\/pbac-meetings\/psd\/2016-11\/files\/brentuximab-post-asct-psd-november-2016.pdf."},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.13.2615"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-12-253856"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08938-9"},{"key":"e_1_2_9_27_1","unstructured":"SMC(2014)Brentuximab vedotin (ADCETRIS\u00ae) 50mg powder for concentrate for solution for infusion. SMC No (845\/12). Scottish Medicines Consortium. Glasgow UK. Available.https:\/\/www.scottishmedicines.org.uk\/media\/1363\/dad_brentuximab_vedotin__adcetris__final_sept_2014_amended_numbering_for_website.pdf."},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-200826090-00006"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-643569"},{"key":"e_1_2_9_30_1","first-page":"214","article-title":"Hodgkin\u2019s lymphoma: the role of cell surface receptors in regulation of tumor cell fate","volume":"32","author":"Yurchenko M.","year":"2010","journal-title":"Experimental Oncology"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjh.16201","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.16201","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bjh.16201","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.16201","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,7]],"date-time":"2023-09-07T17:49:01Z","timestamp":1694108941000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.16201"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,6]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["10.1111\/bjh.16201"],"URL":"https:\/\/doi.org\/10.1111\/bjh.16201","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,6]]},"assertion":[{"value":"2019-05-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-07-15","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-10-06","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}